Previous 10 | Next 10 |
SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of an underwritten public offering of 3,700,000 shares of its common stock at a price to the public of $16.25 per share. All of the s...
Exagen (XGN) has announced an underwritten public offering of common shares.The number of shares to be offered and other financial details were not disclosed.Cowen, William Blair and Cantor Fitzgerald are joint book-runners.Underwriters will be granted a 30-day option to buy an...
SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addi...
Image source: The Motley Fool. Exagen Inc. (NASDAQ: XGN) Q4 2020 Earnings Call Mar 16, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Exagen Inc. (XGN) Q4 2020 Earnings Call Transcript
Exagen Inc. (XGN) Q4 2020 Results Earnings Conference Call March 16, 2021, 4:30 9m ET Company Participants Mike Cavanaugh - Investor Relations, Managing Director at Westwicke Partners Ron Rocca - President, Chief Executive Officer Kamal Adawi - Chief Financial Officer Mark Hazeltine - Chief O...
Exagen (XGN): Q4 GAAP EPS of -$0.27 beats by $0.11.Revenue of $12.67M (+24.1% Y/Y) beats by $1.97M.Press Release For further details see: Exagen EPS beats by $0.11, beats on revenue
SAN DIEGO, March 16, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year ended December 31, 2020. Recent Highlights: Generated total revenue of $42....
SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, will release financial results for the quarter and year ended December 31, 2020 after the market close on Tuesday, March 16, 2021. Ron Rocca, President and Chief Executive O...
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, today announced its participation in the Cowen 41st Annual Health Care Conference which takes place March 1-4, 2021. Ron Rocca, Exagen’s President and Chief Executive ...
SAN DIEGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, today announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 17-19, 2021. Ron Rocca, Exag...
News, Short Squeeze, Breakout and More Instantly...
CARLSBAD, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2024. First Quarter Highlights: Recognized total revenue of $14.4 million in the ...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...
CARLSBAD, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2024, before the market opens on Monday, May 13, 2024. John Aballi, Exagen’s President and Chief Executiv...